Market Place
Sourcing Support
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Kura Reports Proof of Mechanism in Phase 1/2 Trial of Tipifarnib & Alpelisib
26 Oct 2022 //
GLOBENEWSWIRE
Novartis’ new rare disease drug Vijoice meant as `blank canvas`
11 Aug 2022 //
FIERCE PHARMA
New Novartis data show Piqray effectiveness across key biomarkers
06 Jun 2022 //
EXPRESS PHARMA
FDA approves Novartis Vijoice for select patients with PROS
05 Apr 2022 //
GLOBENEWSWIRE
MHRA approves licence extension for Novartis’ targeted therapy for breast cancer
24 Dec 2021 //
PRESS RELEASE
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib
16 Dec 2021 //
GLOBENEWSWIRE
Novartis announces data from a real-world study of alpelisib in people with PROS
17 Sep 2021 //
GLOBENEWSWIRE
Kura Oncology Announces Collaboration to Evaluate Tipifarnib plus Alpelisib
06 Jul 2021 //
GLOBENEWSWIRE
PIQRAY® is approved and now available in Canada as the first and only
13 Aug 2020 //
BIOSPACE
Novartis Europharm `s Piqray (alpelisib) Receives Approval in Europe
31 Jul 2020 //
EMA
EU regulators approve Novartis` breast cancer combo
30 Jul 2020 //
PHARMA TIMES
Novartis receives Piqray® approval in Europe the first & only targeted medicine
29 Jul 2020 //
PRESS RELEASE
New vaccine for Ebola among CHMP recommendations
01 Jun 2020 //
PHARMATIMES
`Friendly` FDA is here to stay with 45 drug approvals in 2019
02 Jan 2020 //
FIERCE BIOTECH
Novartis hopes for 25 more blockbuster nods in the coming years
05 Dec 2019 //
FIERCE PHARMA
Pharming deal shows there`s still life in struggling cancer drug class
16 Aug 2019 //
BIOPHARMADIVE
Employee health benefits’ costs expected to rise 5% in 2020, new survey says
15 Aug 2019 //
CNBC
Novartis` second blockbuster approval barely registers
28 May 2019 //
IN-PHARMATECHNOLOGIST
Novartis` breast cancer treatment wins FDA approval
24 May 2019 //
REUTERS
Novartis drug cut death risk by 35 percent in gene mutation breast cancer
21 Oct 2018 //
REUTERS
Novartis drug cut death risk by 35 percent in gene mutation breast cancer
21 Oct 2018 //
REUTERS
Novartis` SOLAR-1 BYL719 trial meets primary endpoint in HR+/HER2- breast cancer
24 Aug 2018 //
PHARMABIZ
Novartis’ PI3K drug hits goal in phase 3 breast cancer trial
24 Aug 2018 //
FIERCE BIOTECH
Novartis considers filings for PI3K drug in breast cancer
24 Aug 2018 //
PMLIVE
Novartis succeeds where Roche failed with PI3K breast cancer drug
23 Aug 2018 //
PHARMAPHORUM
Novartis just boasted of a big PhIII PI3K success
23 Aug 2018 //
ENDPTS
Novartis trial win lifts profile of new breast cancer drug
23 Aug 2018 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.